Dianthus therapeutics highlights recent business achievements and reports q1 financial results

Phase 2 magic trial in generalized myasthenia gravis (gmg) ongoing, with top-line results anticipated in 2h'25 building a neuromuscular franchise with dnth103; phase 2 trial in multifocal motor neuropathy (mmn) to initiate 2q'24 and phase 2 trial in chronic inflammatory demyelinating polyneuropathy (cidp) to initiate 2h'24 $377 million of cash, including proceeds from a successful $230 million pipe financing completed in january 2024, provides runway into 2h 2027 new york and waltham, mass., may 09, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending march 31, 2024, and provided an update on recent business achievements.
DNTH Ratings Summary
DNTH Quant Ranking